Back to top
more

ANI Pharmaceuticals (ANIP)

(Delayed Data from NSDQ)

$66.14 USD

66.14
85,940

+0.57 (0.86%)

Updated Apr 23, 2024 04:00 PM ET

After-Market: $66.06 -0.08 (-0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Company Summary

ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN.

General Information

ANI Pharmaceuticals, Inc

210 Main Street West

Baudette, MN 56623

Phone: 218-634-3500

Fax: 218-634-3540

Web: http://www.anipharmaceuticals.com

Email: ir@anipharmaceuticals.com

Industry Medical - Biomedical and Genetics
Sector Medical
Fiscal Year End December
Last Reported Quarter 3/31/2024
Earnings Date

This is a confirmed date of earnings release. Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Information Providers, or gathered by Zacks Investment Research, Inc. from publicly available sources. There may be delays, omissions, or inaccuracies in the Information.

 5/10/2024

EPS Information

Current Quarter EPS Consensus Estimate 0.97
Current Year EPS Consensus Estimate 4.43
Estimated Long-Term EPS Growth Rate NA
Earnings Date

This is a confirmed date of earnings release. Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Information Providers, or gathered by Zacks Investment Research, Inc. from publicly available sources. There may be delays, omissions, or inaccuracies in the Information.

 5/10/2024

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 65.58
52 Week High 70.81
52 Week Low 36.99
Beta 0.79
20 Day Moving Average 143,276.55
Target Price Consensus 79.80

ANIP

% Price Change
4 Week -5.72
12 Week 19.27
YTD 19.01
% Price Change Relative to S&P 500
4 Week -1.81
12 Week 17.30
YTD 13.29
Share Information
Shares Outstanding (millions) 21.08
Market Capitalization (millions) 1,383.20
Short Ratio NA
Last Split Date 7/18/2013
Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio 0.00
Change in Payout Ratio 0.00
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E
P/E (F1) 14.81
Trailing 12 Months 13.90
PEG Ratio NA
EPS Growth
vs. Previous Year 32.20%
vs. Previous Quarter -25.71%
   
Sales Growth
vs. Previous Year 39.71%
vs. Previous Quarter -0.13%
   
Price Ratios
Price/Book 3.11
Price/Cash Flow 10.23
Price / Sales 2.84
ROE
3/31/24 NA
12/31/23 18.06
9/30/23 17.96
ROA
3/31/24 NA
12/31/23 8.38
9/30/23 8.05
Current Ratio
3/31/24 NA
12/31/23 3.57
9/30/23 3.70
Quick Ratio
3/31/24 NA
12/31/23 2.81
9/30/23 2.91
Operating Margin
3/31/24 NA
12/31/23 14.72
9/30/23 14.67
Net Margin
3/31/24 NA
12/31/23 3.86
9/30/23 2.98
Pre-Tax Margin
3/31/24 NA
12/31/23 4.08
9/30/23 2.94
Book Value
3/31/24 NA
12/31/23 21.13
9/30/23 21.07
Inventory Turnover
3/31/24 NA
12/31/23 1.71
9/30/23 1.57
Debt-to-Equity
3/31/24 NA
12/31/23 0.66
9/30/23 0.66
Debt to Capital
3/31/24 NA
12/31/23 38.36
9/30/23 38.53